Why is Kilitch Drugs (India) Ltd ?
- NET SALES(Q) At Rs 44.88 cr has Fallen at -23.8% (vs previous 4Q average)
- PAT(Q) At Rs 2.91 cr has Fallen at -61.4% (vs previous 4Q average)
- DEBT-EQUITY RATIO(HY) Highest at 0.32 times
- Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Kilitch Drugs for you?
High Risk, High Return
Quality key factors
Valuation Key Factors 
Technical key factors
Technical Movement
At Rs 134.48 cr has Grown at 28.85%
At Rs 17.43 cr has Grown at 29.78%
At Rs 44.88 cr has Fallen at -23.8% (vs previous 4Q average
At Rs 2.91 cr has Fallen at -61.4% (vs previous 4Q average
Highest at 0.32 times
Lowest at 1.96 times
Lowest at Rs 2.93 cr.
Lowest at 6.53%
is 75.13 % of Profit Before Tax (PBT
Lowest at Rs 0.83
Here's what is not working for Kilitch Drugs
Net Sales (Rs Cr)
PAT (Rs Cr)
Operating Profit (Rs Cr)
Operating Profit to Sales
Non Operating Income to PBT
EPS (Rs)
Debt-Equity Ratio
Debtors Turnover Ratio






